世界の非アルコール性脂肪性肝炎（NASH）治療薬＆診断市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-4585 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、非アルコール性脂肪性肝炎（NASH）治療薬＆診断の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（治療、診断）、用途別市場規模（病院、クリニック）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・非アルコール性脂肪性肝炎（NASH）治療薬＆診断の市場動向 ・企業の競争状況、市場シェア ・非アルコール性脂肪性肝炎（NASH）治療薬＆診断の種類別市場規模と予測2016-2027（治療、診断） ・非アルコール性脂肪性肝炎（NASH）治療薬＆診断の用途別市場規模と予測2016-2027（病院、クリニック） ・非アルコール性脂肪性肝炎（NASH）治療薬＆診断の北米市場規模2016-2027（アメリカ、カナダ） ・非アルコール性脂肪性肝炎（NASH）治療薬＆診断の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・非アルコール性脂肪性肝炎（NASH）治療薬＆診断のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・非アルコール性脂肪性肝炎（NASH）治療薬＆診断の中南米市場規模2016-2027（メキシコ、ブラジル） ・非アルコール性脂肪性肝炎（NASH）治療薬＆診断の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Siemens Healthcare、Celerion、ZyVersa Therapeutics, Inc.、Cisbio、Regeneron Pharmaceuticals, Inc.、BioPredictive、Echosens、Genfit、Enterome、NGM Biopharmaceuticals） ・結論

Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.

Market Analysis and Insights: Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
The global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market.

Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Scope and Market Size
Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Therapeutics
Diagnostics

Segment by Application
Hospital
Clinic

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Therapeutics
1.2.3 Diagnostics
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Perspective (2016-2027)
2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Growth Trends by Regions
2.2.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Share by Regions (2016-2021)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027)
2.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Dynamic
2.3.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Trends
2.3.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Revenue (2016-2021)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Players (2016-2021)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2020
3.5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Type (2016-2021)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027)

5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Application (2016-2021)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
6.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
6.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
6.2.3 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
6.3.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
6.3.3 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country
6.4.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021)
6.4.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
7.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
7.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
7.2.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
7.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
7.3.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country
7.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021)
7.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
8.2.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
8.3.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region
8.4.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
9.2.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
9.2.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
9.2.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
9.3.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
9.3.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
9.3.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country
9.4.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021)
9.4.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2016-2027)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
10.2.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2027)
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
10.3.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2027)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country
10.4.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Siemens Healthcare
11.1.1 Siemens Healthcare Company Details
11.1.2 Siemens Healthcare Business Overview
11.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.1.4 Siemens Healthcare Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.1.5 Siemens Healthcare Recent Development
11.2 Celerion
11.2.1 Celerion Company Details
11.2.2 Celerion Business Overview
11.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.2.4 Celerion Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.2.5 Celerion Recent Development
11.3 ZyVersa Therapeutics, Inc.
11.3.1 ZyVersa Therapeutics, Inc. Company Details
11.3.2 ZyVersa Therapeutics, Inc. Business Overview
11.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.3.4 ZyVersa Therapeutics, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.3.5 ZyVersa Therapeutics, Inc. Recent Development
11.4 Cisbio
11.4.1 Cisbio Company Details
11.4.2 Cisbio Business Overview
11.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.4.4 Cisbio Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.4.5 Cisbio Recent Development
11.5 Regeneron Pharmaceuticals, Inc.
11.5.1 Regeneron Pharmaceuticals, Inc. Company Details
11.5.2 Regeneron Pharmaceuticals, Inc. Business Overview
11.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.5.4 Regeneron Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.5.5 Regeneron Pharmaceuticals, Inc. Recent Development
11.6 BioPredictive
11.6.1 BioPredictive Company Details
11.6.2 BioPredictive Business Overview
11.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.6.4 BioPredictive Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.6.5 BioPredictive Recent Development
11.7 Echosens
11.7.1 Echosens Company Details
11.7.2 Echosens Business Overview
11.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.7.4 Echosens Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.7.5 Echosens Recent Development
11.8 Genfit
11.8.1 Genfit Company Details
11.8.2 Genfit Business Overview
11.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.8.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.8.5 Genfit Recent Development
11.9 Enterome
11.9.1 Enterome Company Details
11.9.2 Enterome Business Overview
11.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.9.4 Enterome Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.9.5 Enterome Recent Development
11.10 NGM Biopharmaceuticals
11.10.1 NGM Biopharmaceuticals Company Details
11.10.2 NGM Biopharmaceuticals Business Overview
11.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.10.4 NGM Biopharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
11.10.5 NGM Biopharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Therapeutics
Table 3. Key Players of Diagnostics
Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Regions (2016-2021)
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Regions (2022-2027)
Table 10. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Trends
Table 11. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers
Table 12. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges
Table 13. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints
Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Players (2016-2021)
Table 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2020)
Table 17. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Solution and Service
Table 21. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Application (2016-2021)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2022-2027) & (US$ Million)
Table 61. Siemens Healthcare Company Details
Table 62. Siemens Healthcare Business Overview
Table 63. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 64. Siemens Healthcare Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 65. Siemens Healthcare Recent Development
Table 66. Celerion Company Details
Table 67. Celerion Business Overview
Table 68. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 69. Celerion Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 70. Celerion Recent Development
Table 71. ZyVersa Therapeutics, Inc. Company Details
Table 72. ZyVersa Therapeutics, Inc. Business Overview
Table 73. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 74. ZyVersa Therapeutics, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 75. ZyVersa Therapeutics, Inc. Recent Development
Table 76. Cisbio Company Details
Table 77. Cisbio Business Overview
Table 78. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 79. Cisbio Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 80. Cisbio Recent Development
Table 81. Regeneron Pharmaceuticals, Inc. Company Details
Table 82. Regeneron Pharmaceuticals, Inc. Business Overview
Table 83. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 84. Regeneron Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 85. Regeneron Pharmaceuticals, Inc. Recent Development
Table 86. BioPredictive Company Details
Table 87. BioPredictive Business Overview
Table 88. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 89. BioPredictive Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 90. BioPredictive Recent Development
Table 91. Echosens Company Details
Table 92. Echosens Business Overview
Table 93. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 94. Echosens Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 95. Echosens Recent Development
Table 96. Genfit Company Details
Table 97. Genfit Business Overview
Table 98. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 99. Genfit Recent Development
Table 100. Enterome Company Details
Table 101. Enterome Business Overview
Table 102. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 103. Enterome Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 104. Enterome Recent Development
Table 105. NGM Biopharmaceuticals Company Details
Table 106. NGM Biopharmaceuticals Business Overview
Table 107. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 108. NGM Biopharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021) & (US$ Million)
Table 109. NGM Biopharmaceuticals Recent Development
Table 110. Research Programs/Design for This Report
Table 111. Key Data Information from Secondary Sources
Table 112. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type: 2020 VS 2027
Figure 2. Therapeutics Features
Figure 3. Diagnostics Features
Figure 4. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Report Years Considered
Figure 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 9. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 10. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Regions: 2020 VS 2027
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Regions (2022-2027)
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Players in 2020
Figure 13. Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2020
Figure 14. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2020
Figure 15. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2016-2021)
Figure 16. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2022-2027)
Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 18. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 19. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 21. United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 25. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 26. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 27. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Nordic Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 35. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 36. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region (2016-2027)
Figure 37. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Australia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 45. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 46. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 47. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type (2016-2027)
Figure 51. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application (2016-2027)
Figure 52. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2016-2027)
Figure 53. Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. UAE Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Siemens Healthcare Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 57. Celerion Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 58. ZyVersa Therapeutics, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 59. Cisbio Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 60. Regeneron Pharmaceuticals, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 61. BioPredictive Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 62. Echosens Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 63. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 64. Enterome Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 65. NGM Biopharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2016-2021)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

---